A randomized, double-blind, parallel-controlled, phase I clinical study comparing the pharmacokinetic characteristics, safety, and immunogenicity of HWS111 injection and erenumab injection (trade name: Aimovig®) in healthy adult Chinese subjects

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 9376b84bc759ffdcdc74886d0a4b916c7fe31c40
First added on: Sep 12, 2026